Literature DB >> 28184915

MicroRNA-30d inhibits the migration and invasion of human esophageal squamous cell carcinoma cells via the post‑transcriptional regulation of enhancer of zeste homolog 2.

Rui Xie1, Shang-Nong Wu1, Cheng-Cheng Gao1, Xiao-Zhong Yang1, Hong-Gang Wang1, Jia-Ling Zhang1, Wei Yan1, Tian-Heng Ma1.   

Abstract

The present study was carried out to investigate the expression pattern, clinical significance and biological functions of microRNA-30d (miR-30d) in esophageal carcinogenesis. Quantitative real-time PCR was performed to detect the expression levels of miR-30d in esophageal squamous cell carcinoma (ESCC) tissues and cell lines. Then, associations between miR-30d expression and various clinicopathological features of patients with ESCC were statistically evaluated. In addition, the effects of miR-30d on the migration and invasion of two human ESCC cell lines transfected with miRNA or co-transfected with miRNA mimics and the expression vector of its target gene were determined. The results revealed that the expression levels of miR-30d were markedly decreased in ESCC tissues and cell lines, comparing with the corresponding normal controls. Notably, reduced expression of miR-30d occurred more frequently in ESCC patients with positive lymph node metastasis, moderate-poor differentiation and advanced tumor-node-metastasis stage than those with negative features. Functionally, enforced expression of miR-30d was found to inhibit cell invasion and migration of the ESCC cell lines. Luciferase reporter assay identified enhancer of zeste homolog 2 (EZH2) as a direct target gene of miR-30d. The expression level of EZH2 mRNA was negatively correlated with the expression of miR-30d in the ESCC tissues. Moreover, the inhibitory effect of miR-30d on ESCC cell motility was reversed by EZH2 overexpression. Collectively, these findings provide convincing evidence that decreased expression of miR-30d may be implicated in esophageal carcinogenesis and progression. We also confirmed miR-30d as a tumor-suppressor which may inhibit cancer cell motility by targeting EZH2, a potential therapeutic target for ESCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28184915     DOI: 10.3892/or.2017.5405

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Plasma microRNA-9 as a diagnostic and prognostic biomarker in patients with esophageal squamous cell carcinoma.

Authors:  Yuantao Cui; Yuan Xue; Shangwen Dong; Peng Zhang
Journal:  J Int Med Res       Date:  2017-06-06       Impact factor: 1.671

2.  Inhibitory effect of microRNA-455-5p on biological functions of esophageal squamous cell carcinoma Eca109 cells via Rab31.

Authors:  Ying Liu; Yanping Tang; Ping Li
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

3.  Urinary microRNA biomarkers for detecting the presence of esophageal cancer.

Authors:  Yusuke Okuda; Takaya Shimura; Hiroyasu Iwasaki; Shigeki Fukusada; Ruriko Nishigaki; Mika Kitagawa; Takahito Katano; Yasuyuki Okamoto; Tamaki Yamada; Shin-Ichi Horike; Hiromi Kataoka
Journal:  Sci Rep       Date:  2021-04-20       Impact factor: 4.379

4.  Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Authors:  Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy
Journal:  Biomolecules       Date:  2021-05-20

Review 5.  EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?

Authors:  Ke-Sin Yan; Chia-Yuan Lin; Tan-Wei Liao; Cheng-Ming Peng; Shou-Chun Lee; Yi-Jui Liu; Wing P Chan; Ruey-Hwang Chou
Journal:  Int J Mol Sci       Date:  2017-05-31       Impact factor: 5.923

6.  MicroRNA-527 Induces Proliferation and Cell Cycle in Esophageal Squamous Cell Carcinoma Cells by Repressing PH Domain Leucine-Rich-Repeats Protein Phosphatase 2.

Authors:  Qingjie Xian; Ronglei Zhao; Juanjuan Fu
Journal:  Dose Response       Date:  2020-05-22       Impact factor: 2.658

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.